{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T19:27:10Z","timestamp":1649100430392},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.antiviral.2013.08.022","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T01:46:35Z","timestamp":1378345595000},"page":"328-336","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates"],"prefix":"10.1016","volume":"100","author":[{"given":"Sonal","family":"Rajyaguru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.08.022_b0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.virol.2004.03.034","article-title":"Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts","volume":"324","author":"Aizaki","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0010","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.antiviral.2013.08.022_b0015","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1128\/JVI.02481-06","article-title":"Allelic variation in the hepatitis C virus NS4B protein dramatically influences RNA replication","volume":"81","author":"Blight","year":"2007","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0020","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1128\/JVI.00858-11","article-title":"Charged residues in hepatitis C virus NS4B are critical for multiple NS4B functions in RNA replication","volume":"85","author":"Blight","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0025","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/JVI.77.5.3181-3190.2003","article-title":"Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture","volume":"77","author":"Blight","year":"2003","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2010.03.013","article-title":"A small molecule inhibits HCV replication and alters NS4B\u2019s subcellular distribution","volume":"87","author":"Bryson","year":"2010","journal-title":"Antiviral Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0035","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1128\/JVI.74.9.4291-4301.2000","article-title":"Virus-specific cofactor requirement and chimeric hepatitis C virus\/GB virus B nonstructural protein 3","volume":"74","author":"Butkiewicz","year":"2000","journal-title":"Journal of Virology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.08.022_b0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1440-1746.2010.06550.x","article-title":"Hepatitis C virus: How genetic variability affects pathobiology of disease","volume":"26","author":"Chayama","year":"2011","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0045","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3390\/v2112481","article-title":"The future of HCV therapy: NS4B as an antiviral target","volume":"2","author":"Dvory-Sobol","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2013.08.022_b0050","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1128\/JVI.78.20.11288-11295.2004","article-title":"A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication","volume":"78","author":"Einav","year":"2004","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hep.22339","article-title":"Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon\/ribavirin combination therapy","volume":"48","author":"El-Shamy","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0031-1297925","article-title":"New insights into the HCV quasispecies and compartmentalization","volume":"31","author":"Farci","year":"2011","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.antiviral.2013.08.022_b0065","doi-asserted-by":"crossref","first-page":"20483","DOI":"10.1074\/jbc.M500422200","article-title":"Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3\/4A protease","volume":"280","author":"Ferreon","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.antiviral.2013.08.022_b0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0168-1702(02)00146-6","article-title":"Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus","volume":"90","author":"Florese","year":"2002","journal-title":"Virus Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0075","doi-asserted-by":"crossref","first-page":"12047","DOI":"10.1128\/JVI.75.24.12047-12057.2001","article-title":"Sequences in the 5\u2032 nontranslated region of hepatitis C virus required for RNA replication","volume":"75","author":"Friebe","year":"2001","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/rmv.640","article-title":"Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory","volume":"20","author":"Gouttenoire","year":"2010","journal-title":"Reviews in Medical Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0085","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.antiviral.2013.08.022_b0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jac\/dkn085","article-title":"Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients","volume":"61","author":"Le Pogam","year":"2008","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.antiviral.2013.08.022_b0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2010.02.003","article-title":"Development of novel therapies for hepatitis C","volume":"86","author":"Lemon","year":"2010","journal-title":"Antiviral Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0160","doi-asserted-by":"crossref","DOI":"10.1111\/j.1462-5822.2012.01773.x","article-title":"Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy","author":"Li","year":"2012","journal-title":"Cellular Microbiology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jviromet.2007.05.016","article-title":"A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations","volume":"145","author":"Middleton","year":"2007","journal-title":"Journal of Virological Methods"},{"key":"10.1016\/j.antiviral.2013.08.022_b0110","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1128\/JVI.00875-08","article-title":"A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication","volume":"82","author":"Paredes","year":"2008","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0115","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1074\/jbc.M808773200","article-title":"Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway","volume":"284","author":"Park","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.antiviral.2013.08.022_b0120","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1128\/JVI.00502-11","article-title":"NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes","volume":"85","author":"Paul","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.08.022_b0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.antiviral.2008.11.002","article-title":"Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates","volume":"81","author":"Qi","year":"2009","journal-title":"Antiviral Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2011.01.009","article-title":"New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B","volume":"90","author":"Rai","year":"2011","journal-title":"Antiviral Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0135","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.antiviral.2013.08.022_b0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.antiviral.2006.07.005","article-title":"Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera","volume":"73","author":"Tripathi","year":"2007","journal-title":"Antiviral Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1261\/rna.5124404","article-title":"Two-step affinity purification of the hepatitis C virus ribonucleoprotein complex","volume":"10","author":"Waris","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.antiviral.2013.08.022_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2012.04.006","article-title":"HCV NS4B induces apoptosis through the mitochondrial death pathway","author":"Zhao","year":"2012","journal-title":"Virus Research"},{"key":"10.1016\/j.antiviral.2013.08.022_b0155","first-page":"529","article-title":"Hepatitis C virus non-structural protein NS4B can modulate an unfolded protein response","volume":"43","author":"Zheng","year":"2005","journal-title":"Journal of Microbiology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213002428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213002428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T11:27:53Z","timestamp":1539430073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213002428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0166354213002428"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.022","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}